A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 12, 2004, Pages 5959-5965

  Herbst, Karen L ^a   Coviello, Andrea D ^b   Page, Stephanie ^b   Amory, John K ^b   Anawalt, Bradley D ^b,c   Bremner, William J ^b  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Puget Sound Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLINE; GONADORELIN ANTAGONIST; GONADOTROPIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTRACEPTION; ERYTHEMA; HUMAN; MALE; PRIORITY JOURNAL; PRURITUS;

ADULT; DRUG ADMINISTRATION SCHEDULE; ERYTHEMA; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PRURITUS; REFERENCE VALUES; TESTOSTERONE; TIME FACTORS;

EID: 10344247116     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-032123     Document Type: Article

References (23)

1. Huirne JA, Lambalk CB 2001 Gonadotropin-releasing-hormone-receptor antagonists. Lancet 358:1793-1803
2. Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Fotheringham N, Campion M, Garnick MB; Abarelix Study Group 2002 A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 167:1670-1674
3. Tarlatzis BC, Bili HN 2003 Gonadorropin-releasing hormone antagonists: impact of IVF practice and potential non-assisted reproductive technology applications. Curr Opin Obstet Gynecol 15:259-264
4. Felberbaum RE, Kupker W, Diedrich K 2002 Will GnRH antagonists assist in the treatment of benign gynaecological diseases? Reprod Biomed Online 5(Suppl 1):68-72
5. Kupker W, Felberbaum RE, Krapp M, Schill T, Malik E, Diedrich K 2002 Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 5:12-16
6. Roth C 2002 Therapeutic potential of GnRH antagonists in the treatment of precocious puberty. Expert Opin Investig Drugs 11:1253-1259
7. Wang C, Swerdloff RS 2004 Male hormonal contraception. Am J Obstet Gynecol 190:860-568
8. Anawalt BD, Amory JK 2001 Advances in male hormonal contraception. Ann Med 33:587-595
9. Herbst KL, Anawalt BD, Amory JK, Bremner WJ 2002 Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 87:3215-3220
10. Rivier JE, Jiang G, Porter J, Hoeger CA, Craig AG, Corrigan A, Vale W, Rivier CL 1995 Gonadotropin-releasing hormone antagonists: novel members of the azaline B family. J Med Chem 38:2649-2662
11. Goldman JM, Cooper RL, Rehnberg GL, Gabel S, McElroy WK, Hein J, Conn PM 1987 Age-related alterations in the stimulated release in vitro of catecholamines and luteinizing hormone-releasing hormone from the male rat hypothalamus. Neurochem Res 12:651-657
12. Jiang G, Gavini E, Dani BA, Murty SB, Schrier B, Thanoo BC, DeLuca PP 2002 Identification and determination of GnRH antagonist gelling at injection site. Int J Pharm 233:19-27
13. Kovacs M, Schally AV, Csernus B, Rekasi Z 2001 Luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH. Proc Natl Acad Sci USA 98:1829-1834
14. Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB 2001 The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 165:1585-1589
15. Behre HM, Klein B, Steinmeyer E, McGregor GP, Voigt K, Nieschlag E 1992 Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men. J Clin Endocrinol Metab 75:393-398
16. Halmos G, Schally AV, Pinski J, Vadillo-Buenfil M, Groot K 1996 Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist cetrorelix. Proc Natl Acad Sci USA 93: 2398-2402
17. Pinski J, Lamharzi N, Halmos G, Groot K, Jungwirth A, Vadillo-Buenfil M, Kakar SS, Serially AV 1996 Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. Endocrinology 137:3430-3436
18. Kovacs M, Serially AV 2001 Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats. Proc Natl Acad Sci USA 98:12197-12202
19. Seidman SN 2001 Testosterone deficiency and depression in aging men: pathogenic and therapeutic implications. J Gend Specif Med 4:44-48
20. Zitzmann M, Nieschlag E 2000 Hormone substitution in male hypogonadism. Mol Cell Endocrinol 161:73-88
21. Fisher JW, Langsten JW 1968 Effects of testosterone, cobalt and hypoxia on erythropoietin production in the isolated perfused dog kidney. Ann NY Acad Sci 149:75-87
22. Naets JP, Wittek M 1968 The mechanism of action of androgens on erythropoiesis. Ann NY Acad Sci 149:366-376
23. Weber JP, Walsh PC, Peters CA, Spivak JL 1991 Effect of reversible androgen deprivation on hemoglobin and serum immunoreacrive erythropoietin in men. Am J Hematol 36:190-194